Kowa Pharmaceuticals America, Inc. Receives Pediatric Indication and Six-Month Pediatric Exclusivity for LIVALO® (pitavastatin)
MONTGOMERY, Ala.–(BUSINESS WIRE)–Kowa Pharmaceuticals America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the cholesterol-lowering…